Cargando…

Response to Comment on: “Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients”

Detalles Bibliográficos
Autor principal:	Brown, Jennifer R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2021
Materias:	Response
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9152971/ https://www.ncbi.nlm.nih.gov/pubmed/34788990 http://dx.doi.org/10.3324/haematol.2021.280310

Ejemplares similares

Comment on: “Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients”
por: Visentin, Andrea, et al.
Publicado: (2021)

Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients
por: Brown, Jennifer R., et al.
Publicado: (2021)

The role of acalabrutinib in adults with chronic lymphocytic leukemia
por: Fakhri, Bita, et al.
Publicado: (2021)

Acalabrutinib in management of chronic lymphocytic leukemia: An Indian perspective
por: Sood, Nitin, et al.
Publicado: (2021)

Acalabrutinib in Membranous Nephropathy Associated With Chronic Lymphocytic Leukemia
por: Izzedine, Hassan, et al.
Publicado: (2022)

COVID-19 Infection in Patients With Chronic Lymphocytic Leukemia Receiving Acalabrutinib in the Phase 3B ASSURE Study
por: Niemann, Carsten U., et al.
Publicado: (2022)

Phase I/II results of ceralasertib as monotherapy or in combination with acalabrutinib in high-risk relapsed/refractory chronic lymphocytic leukemia
por: Jurczak, Wojciech, et al.
Publicado: (2023)

Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia
por: Roeker, Lindsey E., et al.
Publicado: (2023)

Targeted Treatment of Chronic Lymphocytic Leukemia: Clinical Utility of Acalabrutinib
por: Vitale, Candida, et al.
Publicado: (2021)

Phase II study of acalabrutinib in ibrutinibintolerant patients with relapsed/refractory chronic lymphocytic leukemia
por: Rogers, Kerry A., et al.
Publicado: (2021)

P599: ACALABRUTINIB IMPROVES INNATE IMMUNE FUNCTION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
por: Teglgaard, Rebecca, et al.
Publicado: (2023)

Response to “Comments on Economic Evaluation of Ultrasound-guided Central Venous Catheter Confirmation vs Chest Radiography in Critically Ill Patients: A Labor Cost Model”
por: Ablordeppey, Enyo A., et al.
Publicado: (2023)

NICE recommends acalabrutinib for chronic lymphocytic leukaemia
Publicado: (2021)

Human rights and COVID-19 triage: a comment on the Bath protocol
por: Bhatt, Vivek, et al.
Publicado: (2021)

Response: Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019;43:582–9)
por: Hwang, You-Cheol
Publicado: (2019)

Acalabrutinib-Related Cardiac Toxicities in Patients with Chronic Lymphocytic Leukemia: A Meta-Analysis of Randomized Controlled Trials
por: Htut, Thura Win, et al.
Publicado: (2021)

Acalabrutinib for mantle cell lymphoma, chronic lymphocytic leukaemia
Publicado: (2020)

Acalabrutinib and high-frequency low-dose subcutaneous rituximab for initial therapy of chronic lymphocytic leukemia
por: Wallace, Danielle S., et al.
Publicado: (2023)

Response to a Comment on “Scar‐Degrading Endothelial Cells as a Treatment for Advanced Liver Fibrosis”
por: Zhao, Peng, et al.
Publicado: (2023)

Reply to comments on prone CPR for COVID-19 patients
por: Singh, Baljit, et al.
Publicado: (2020)

Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial
por: Seymour, John F., et al.
Publicado: (2023)

Response to the comments raised by the readers to our published article “An observational case-control study comparing the recovery profile in patients receiving additional dose of anticonvulsant vs. regular dose during supratentorial craniotomy.”
por: Mariappan, Ramamani, et al.
Publicado: (2020)

Response: Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study (Diabetes Metab J 2019;43:640–8)
por: Chung, Yoo-Ri, et al.
Publicado: (2019)

Acalabrutinib and Its Therapeutic Potential in the Treatment of Chronic Lymphocytic Leukemia: A Short Review on Emerging Data
por: Isaac, Krista, et al.
Publicado: (2020)

Acalabrutinib Versus Investigator’s Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results
por: Ghia, Paolo, et al.
Publicado: (2022)

Acalabrutinib and steroid for autoimmune thrombocytopenia due to relapsed chronic lymphocytic leukemia with severe bone marrow infiltration
por: Oyama, Takashi, et al.
Publicado: (2023)

Guest authorship: the practice of author pooling
por: Bhaskar, Emmanuel
Publicado: (2010)

Real-World Comparison of First-Line Treatment Adherence Between Single-Agent Ibrutinib and Acalabrutinib in Patients with Chronic Lymphocytic Leukemia
por: Lu, Xiaoxiao, et al.
Publicado: (2023)

Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
por: Byrd, John C., et al.
Publicado: (2021)

Reply to the “Comment on ‘A Pumpless Microfluidic Neonatal Lung Assist Device for Support of Preterm Neonates in Respiratory Distress’” by Li Wang, Fang Li, Zhichun Feng, Yuan Shi
por: Rochow, Niels, et al.
Publicado: (2021)

PB1925: NAOS STUDY: FIRST INTERIM ANALYSIS OF ACALABRUTINIB USE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN A REAL-LIFE SETTING.
por: Quinquenel, Anne, et al.
Publicado: (2023)

Response to comments: Continuous incremental interscalene block for proximal humerus in patients with severe pulmonary injury
por: Diwan, Sandeep, et al.
Publicado: (2022)

Response: Cardiovascular Disease Predicts Severe Hypoglycemia in Patients with Type 2 Diabetes (Diabetes Metab J 2015;39:498-506)
por: Yun, Jae-Seung, et al.
Publicado: (2016)

Response to M Krkošek, C W Revie, B Finstad and C D Todd's comment on Jackson et al. ‘Impact of Lepeophtheirus salmonis infestations on migrating Atlantic salmon, Salmo salar L., smolts at eight locations in Ireland with an analysis of lice-induced marine mortality’
por: Jackson, D, et al.
Publicado: (2014)

Increased Risk of Cardiovascular Disease and Mortality in Patients with Diabetes and Coexisting Depression: A Nationwide Population-Based Cohort Study (Diabetes Metab J 2021;45:379-89)
por: Jung, Inha, et al.
Publicado: (2021)

Response to “Comment on ‘COVID-19, the Built Environment, and Health’”
por: Frumkin, Howard
Publicado: (2021)

Response to: Comment on The AI and I: A Collaboration on Competence
por: Funk, Luke M., et al.
Publicado: (2023)

Response to Comment to the Article “Are There Differences in Gut Microbiome in Patients with Type 2 Diabetes Treated by Metformin or Metformin and Insulin?” [Response To Letter]
por: Dzięgielewska-Gęsiak, Sylwia, et al.
Publicado: (2022)

Response to: Comment on “Laparoscopic Paraesophageal Hernia Repair: to Mesh or Not to Mesh”
por: Schlottmann, Francisco
Publicado: (2023)

PB1929: EFFICACY AND SAFETY OF ACALABRUTINIB IN CHINESE PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: AN OPEN-LABEL, MULTICENTER PHASE 1/2 TRIAL
por: Yang, Shenmiao, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5r7ht8b8h6i60s24bftf433keq